Crohns Disease Therapeutics Market Demand and Forecast | 2031

Crohn's Disease Therapeutics Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-inflammatory Drugs, Immune System Suppressors, Antibiotics, Biologics, Anti-diarrheal, and Pain Relievers), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

  • Report Code : TIPRE00004296
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Crohns Disease Therapeutics Market Demand and Forecast | 2031

Buy Now

[Research Report] The Crohn's disease therapeutics market was valued at US$ 9.68 billion in 2023 and is projected to reach US$ 13.33 billion by 2031. It is expected to register a CAGR of 4.1% in 2023–2031.

Market Insights and Analyst View:

Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive in the market are fueling market growth. A significant increase in the usage of advanced medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.

Growth Drivers and Challenges:

Crohn's disease is an irritable bowel syndrome, a chronic inflammatory bowel disorder with no specific cure. The exact etiology of this disease is not known, but the condition is mainly the result of an inappropriate immune response in the bowel to drugs, toxins, infections, and intestinal microbes, among other environmental factors, especially in a genetically susceptible host. According to National Library of Medicine, Crohn's disease (CD) is more common in developed countries in the West, especially in North American and northern European countries, and New Zealand. The disease onset is most common in individuals aged 15–30 years and 40–60 years, and it is more prominent in urban areas. The incidence of this disease is high in people from northern European countries and Jewish descent, i.e., 3.2/1,000. However, recent studies have shown a significant increase in incidence in Asia, Africa, and Australasia as well due to rapid industrialization in the region. Thus, the staggering prevalence of Crohn's disease in the respective region boosts the Crohn's disease therapeutics market.

According to National Institute of Health, Crohn's disease poses a significant economic burden with direct healthcare costs of approximately US$ 3,500 per patient per year in Europe. The disease affects approximately 322 people per 100,000. However, the prevalence rates may vary depending on countries to countries. More than 50% of patients with Crohn's disease may not be formally diagnosed, or they may show symptoms that are the same as those of other digestive tract diseases. Crohn's disease is more common in women as compared to men, i.e., it may affect three times more women than men.

Companies involved in drug development for irritable bowel syndrome are taking constructive steps to implement awareness programs with an aim to effectively cope with this syndrome by spreading awareness about symptoms, diagnoses, and treatments. In 2018, Allergan PLC and Ironwood, in collaboration, launched an Interactive Digital Destination platform to encourage sufferers to get educated and take action against digestive tract disorders. Thus, the rising prevalence of irritable bowel syndrome drives the Crohn's disease therapeutics market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Crohn's Disease Therapeutics Market: Strategic Insights

crohns-disease-therapeutics-market
Market Size Value inUS$ 9.68 billion in 2023
Market Size Value byUS$ 13.33 billion by 2031
Growth rateCAGR of 4.1% from 2023 to 2031
Forecast Period2023-2031
Base Year2023
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The Crohn's disease therapeutics market analysis has been carried out by considering the following segments: drug type, distribution channel, and geography. By drug class, the market is segmented into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal, and pain relievers. The biologics segment held the largest market share in 2023. The anti-inflammatory drugs segment is expected to record the highest CAGR during 2023–2031.

Based on end user, the market is divided into hospital pharmacies, clinical pharmacies, and online others. The hospital pharmacy segment accounted for the largest Crohn's disease therapeutics market share in 2023. In terms of geography, the scope of the Crohn's disease therapeutics market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Regional Analysis:

North America is the largest contributor to the global Crohn's disease therapeutics market growth. Asia Pacific is estimated to record the highest CAGR in the market during 2023–2031. The market progress in North America is attributed to the growing incidence of chronic diseases, technological advancements and access to technologically advanced medical products, the surging geriatric population, and the presence of key market players involved in new and existing product developments. The US held the largest Crohn's disease therapeutics market share in North America in 2023.

Crohns Disease Therapeutics Market Report Scope

Industry Developments and Future Opportunities:

The Crohn's disease therapeutics market forecast is estimated on the basis of various secondary and primary research findings, such as key company publications, association data, and databases. As per the company press releases, key developments by major players operating in the Crohn's disease therapeutics market are listed below:

  • In 2023, the US Food and Drug Administration (FDA) approved the first oral pill—Rinvoq (upadacitinib)—to treat moderate-to-severe Crohn's disease. Rinvoq is meant to treat adult patients who could not be treated successfully with drug candidates blocking tumor necrosis factor (TNF).
  • In 2022, the FDA approved Skyrizi for the treatment of adults with moderate-to-severe active Crohn's disease cases.
  • In 2021, AbbVie Inc. announced the initiation of the Phase 3 trial of risankizumab for the treatment of Crohn's disease. Risankizumab is a humanized monoclonal antibody that selectively targets the interleukin-23 (IL-23) pathway. The trial is aimed at evaluating the efficacy and safety of risankizumab in patients with moderate-to-severe Crohn's disease.
  • In 2021, Takeda Pharmaceutical Company Limited announced the initiation of the Phase 3 trial of the oral compound TAK-721 for the treatment of Crohn's disease. TAK-721 is a selective antagonist of the chemokine receptor CXCR3. The trial is aimed at evaluating the efficacy and safety of TAK-721 in patients with moderate-to-severe Crohn's disease.

Competitive Landscape and Key Companies:

Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim GmbH are among the prominent players profiled in the Crohn's disease therapeutics market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem. These companies focus on geographic expansions and new product launches to meet the growing demand from consumers worldwide and expand their product range with specialty portfolios. Their global presence allows them to serve a large customer base, subsequently facilitating market expansion.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Drug Class, Distribution Channel, and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the driving and restraining factors for the Crohn’s Disease Therapeutics Market?

The increasing burden of irritable bowel syndrome, and the increasing in number of FDA approval and drug development bolster the Crohn’s disease therapeutics market size. However, the high cost of the treatment hinders the Crohn’s disease therapeutics market growth.

Which region is dominating the Crohn’s Disease Therapeutics Market?

Based on geography, the Crohn’s Disease Therapeutics Market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global Crohn’s Disease Therapeutics Market. Asia Pacific is expected to register the highest CAGR in the Crohn’s Disease Therapeutics Market during 2023–2031.

Which segment is dominating the Crohn’s Disease Therapeutics Market?

The Crohn’s disease therapeutics market, based on drug class, is segmented into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal, and pain reliever. In 2023, the biologics segment held the largest Crohn’s disease therapeutics market share. The Crohn’s disease therapeutics market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy, online pharmacy. In 2023, the hospital pharmacy segment held the largest Crohn’s disease therapeutics market share and is anticipated to record the highest CAGR during 2023–2031.

Who are the major players in market the Crohn’s Disease Therapeutics Market?

The Crohn’s Disease Therapeutics Market majorly consists of the players such Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim Gmbh

What is Crohn’s disease therapeutics Market?

Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive in the market are fueling market growth. A significant increase in the use of medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.

The List of Companies - Crohn's Disease Therapeutics Market

  1. ABBVIE, INC.
  2. JOHNSON AND JOHNSON PRIVATE LIMITED
  3. GLAXOSMITHKLINE PLC
  4. MERCK AND CO., INC.
  5. NOVARTIS AG
  6. CELGENE CORPORATION
  7. GENENTECH
  8. PFIZER INC.
  9. NESTLe HEALTH SCIENCE
  10. BOEHRINGER INGELHEIM GMBH

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..